Key result
CCR1 deletion or pharmacological blockade prevents obesity and insulin resistance in high-fat diet-fed mice.
Why the study?
Adipose tissue remodelling holds promise for combating obesity, but the endogenous chemokine receptors that restrain this plasticity remain ill-defined.
CCR1 inhibition promotes fat browning and protects against obesity via cAMP/PKA/CREB signaling and M2 macrophage polarization in a mouse model.
CCR1 inhibition may confer metabolic benefits in mice; leaves open translation to human obesity therapy.
BACKGROUND: Adipose tissue remodelling, encompassing white adipose tissue (WAT) browning alongside brown adipose tissue (BAT) activation, holds promise for combating obesity, yet the endogenous chemokine receptors that restrain this plasticity remain ill-defined. Here, we uncover that C‒C chemokine receptor 1 (CCR1) restrains adipocyte remodelling and energy expenditure. METHODS: A high-fat diet (HFD) was provided to systemic and adipocyte-specific Ccr1 knockout mice. The CCR1-selective antagonist BX471 was administered to HFD-fed wild-type (WT) mice as a preventive regimen. Energy expenditure was assessed via indirect calorimetry; BAT thermogenic activity and WAT beiging were quantified through histology and gene expressin analyses. Adipose tissue macrophage homeostasis was analysed via flow cytometry. Peritoneal macrophages were differentiated into either the M1 or M2 state, and conditioned media were applied to the adipocytes. RESULTS: In HFD-fed mice, Ccr1 ablation conferred resistance to obesity and insulin resistance, coupled with enhanced WAT browning, augmented BAT thermogenesis and elevated energy expenditure. These metabolic benefits were associated with a shift towards M2 macrophage polarisation and reduced adipose tissue inflammation. Adipocyte-specific Ccr1 knockout recapitulated these phenotypes. BX471 administration in WT mice phenocopied the metabolic effects of Ccr1 deficiency under HFD conditions. Mechanistically, in vitro experiments suggested that Ccr1 loss suppressed Gαi-dependent signalling, leading to increased intracellular cyclic adenosine monophosphate (cAMP) and subsequent protein kinase A/cAMP-response element-binding protein 1 (PKA/CREB) activation, thereby promoting thermogenic gene expression in adipocytes. In addition, conditioned media from M2-polarised macrophages enhanced thermogenic gene expression in adipocytes, and this effect was further potentiated in Ccr1-deficient adipocytes. CONCLUSION: CCR1 regulates adipose tissue remodelling and systemic energy expenditure, at least in part, through cAMP/PKA/CREB signalling and macrophage homeostasis. Pharmacological inhibition of CCR1 attenuates obesity development, suggesting a potential preventive strategy. KEY POINTS: CCR1 expression is significantly elevated in adipose tissue of obese individuals. Systemic and adipocyte-specific Ccr1 deletion promotes fat browning via cAMP/PKA/CREB activation and M2 macrophage polarisation, protecting against obesity. Pharmacological blockade of CCR1 suppresses obesity progression, highlighting its potential as a novel target for metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied Obesity. Ccr1 knockout and BX471 (CCR1-selective antagonist) vs. Wild-type mice was evaluated on Obesity, insulin resistance, and adipose tissue remodelling. Systemic and adipocyte-specific Ccr1 deletion, as well as pharmacological blockade with BX471, conferred resistance to obesity and insulin resistance in high-fat diet-fed mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: